Induction of erythroid differentiation in human erythroleukemia cells by depletion of malic enzyme 2

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-12

  Ren, Jian Guo ^a   Seth, Pankaj ^a   Everett, Peter ^a   Clish, Clary B ^b   Sukhatme, Vikas P ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN; GLYCOPHORIN A; MALATE DEHYDROGENASE (DECARBOXYLATING); MALIC ENZYME 2; PYRIMIDINE; TRANSCRIPTION FACTOR GATA 1; UNCLASSIFIED DRUG; VIMENTIN; MALATE DEHYDROGENASE; MALIC ENZYME 2; HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL LINEAGE; CONTROLLED STUDY; ENZYME INHIBITION; ERYTHROID CELL; ERYTHROLEUKEMIA; ERYTHROLEUKEMIA CELL; GENE INDUCTION; GENE SILENCING; HUMAN; HUMAN CELL; MALE; METABOLOMICS; MOUSE; NONHUMAN; OXIDATION; PHENOTYPE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN METABOLISM; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; CELL PROLIFERATION; CELL STRAIN K 562; CYTOLOGY; ENZYMOLOGY; GENE INACTIVATION; GENETICS; PATHOPHYSIOLOGY;

MUS MUSCULUS;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; ERYTHROID CELLS; GENE KNOCKOUT TECHNIQUES; HUMANS; K562 CELLS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MALATE DEHYDROGENASE; MICE;

EID: 77958537945     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012520     Document Type: Article

References (65)

1. Baggetto LG (1992) Deviant energetic metabolism of glycolytic cancer cells. Biochimie 74: 959-974.
2. Moreadith RW, Lehninger AL (1984) The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role of mitochondrial NAD(P)+- dependent malic enzyme. J Biol Chem 259: 6215-6221.
3. Pongratz RL, Kibbey RG, Shulman GI, Cline GW (2007) Cytosolic and mitochondrial malic enzyme isoforms differentially control insulin secretion. J Biol Chem 282: 200-207.
4. Guay C, Madiraju SR, Aumais A, Joly E, Prentki M (2007) A role for ATPcitrate lyase, malic enzyme, and pyruvate/citrate cycling in glucose-induced insulin secretion. J Biol Chem 282: 35657-35665.
5. Ronnebaum SM, Ilkayeva O, Burgess SC, Joseph JW, Lu D, et al. (2006) A pyruvate cycling pathway involving cytosolic NADP-dependent isocitrate dehydrogenase regulates glucose-stimulated insulin secretion. J Biol Chem 281: 30593-30602.
6. Greenberg DA, Cayanis E, Strug L, Marathe S, Durner M, et al. (2005) Malic enzyme 2 may underlie susceptibility to adolescent-onset idiopathic generalized epilepsy. Am J Hum Genet 76: 139-146.
7. Lee BD, Walss-Bass C, Thompson PM, Dassori A, Montero PA, et al. (2007) Malic enzyme 2 and susceptibility to psychosis and mania. Psychiatry Res 150: 1-11.
8. Wasilenko WJ, Marchok AC (1985) Malic enzyme and malate dehydrogenase activities in rat tracheal epithelial cells during the progression of neoplasia. Cancer Lett 28: 35-42.
9. Sauer LA, Dauchy RT, Nagel WO, Morris HP (1980) Mitochondrial malic enzymes. Mitochondrial NAD(P)+-dependent malic enzyme activity and malatedependent pyruvate formation are progression-linked in Morris hepatomas. J Biol Chem 255: 3844-3848.
10. Nagel WO, Dauchy RT, Sauer LA (1980) Mitochondrial malic enzymes. An association between NAD(P)+-dependent malic enzyme and cell renewal in Sprague-Dawley rat tissues. J Biol Chem 255: 3849-3854.
11. Hung HC, Chien YC, Hsieh JY, Chang GG, Liu GY (2005) Functional roles of ATP-binding residues in the catalytic site of human mitochondrial NAD(P)+- dependent malic enzyme. Biochemistry 44: 12737-12745.
12. Loeber G, Infante AA, Maurer-Fogy I, Krystek E, Dworkin MB (1991) Human NAD(+)-dependent mitochondrial malic enzyme. cDNA cloning, primary structure, and expression in Escherichia coli. J Biol Chem 266: 3016-3021.
13. Sauer LA (1973) An NAD- and NADP-dependent malic enzyme with regulatory properties in rat liver and adrenal cortex mitochondrial fractions. Biochem Biophys Res Commun 50: 524-531.
14. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566.
15. Shiotsu Y, Neckers LM, Wortman I, An WG, Schulte TW, et al. (2000) Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemiacells through destabilization of Bcr-Abl with Hsp90 complex. Blood 96: 2284-2291.
16. Kohmura K, Miyakawa Y, Kawai Y, Ikeda Y, Kizaki M (2004) Different roles of p38 MAPK and ERK in STI571-induced multi-lineage differentiation of K562 cells. J Cell Physiol 198: 370-376.
17. Ren JG, Zheng RL, Shi YM, Gong B, Li JF (1998) Apoptosis, redifferentiation and arresting proliferation simultaneously triggered by oxidative stress in human hepatoma cells. Cell Biol Int 22: 41-49.
18. Vafa O, Wade M, Kern S, Beeche M, Pandita TK, et al. (2002) c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 9: 1031-1044.
19. Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, et al. (2000) The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 275: 24273-24278.
20. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, et al. (1997) Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275: 1649-1652.
21. Beckman BS, Balin AK, Allen RG (1989) Superoxide dismutase induces differentiation of Friend erythroleukemia cells. J Cell Physiol 139: 370-376.
22. Nagy K, Pasti G, Bene L, Nagy I (1995) Involvement of Fenton reaction products in differentiation induction of K562 human leukemia cells. Leuk Res 19: 203-212.
23. Oravecz K, Kalka D, Jeney F, Cantz M, Zs-Nagy I (2002) Hydroxyl free radicals induce cell differentiation in SK-N-MC neuroblastoma cells. Tissue Cell 34: 33-38.
24. Lopez-Alarcon L, Eboli ML (1986) Oxidation of reduced cytosolic nicotinamide adenine dinucleotide by the malate-aspartate shuttle in the K-562 human leukemia cell line. Cancer Res 46: 5589-5591.
25. Meshkini A, Yazdanparast R (2008) Involvement of ERK/MAPK pathway in megakaryocytic differentiation of K562 cells induced by 3-hydrogenkwadaphnin. Toxicol In Vitro 22: 1503-1510.
26. Missiroli S, Etro D, Buontempo F, Ye K, Capitani S, et al. (2009) Nuclear translocation of active AKT is required for erythroid differentiation in erythropoietin treated K562 erythroleukemia cells. Int J Biochem Cell Biol 41: 570-577.
27. Kang SK, Lee JY, Chung TW, Kim CH (2004) Overexpression of transglutaminase 2 accelerates the erythroid differentiation of human chronic myelogenous leukemia K562 cell line through PI3K/Akt signaling pathway. FEBS Lett 577: 361-366.
28. Kubohara Y, Hosaka K (1999) The putative morphogen, DIF-1, of Dictyostelium discoideum activates Akt/PKB in human leukemia K562 cells. Biochem Biophys Res Commun 263: 790-796.
29. Suzuki M, Moriguchi T, Ohneda K, Yamamoto M (2009) Differential contribution of the Gata1 gene hematopoietic enhancer to erythroiddifferentiation. Mol Cell Biol 29: 1163-1175.
30. Jarvinen M, Andersson LC, Virtanen I (1990) K562 erythroleukemia cells express cytokeratins 8, 18, and 19 and epithelial membrane antigen that disappear after induced differentiation. J Cell Physiol 143: 310-320.
31. Matsumoto SS, Fujitaki JM, Nord LD, Willis RC, Lee VM, et al. (1990) Inhibition of pyrimidine metabolism in myeloid leukemia cells by triazole and pyrazole nucleosides. Biochem Pharmacol 39: 455-462.
32. Boren J, Cascante M, Marin S, Comin-Anduix B, Centelles JJ, et al. (2001) Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J Biol Chem 276: 37747-37753.
33. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, et al. (2005) ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8: 311-321.
34. French D, Yang W, Cheng C, Raimondi SC, Mullighan CG, et al. (2009) Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood 113: 4512-4520.
35. Lanoue KF, Schoolwerth AC. (1979) Metabolite transport in mitochondria. Annu Rev Biochem 48: 871-922.
36. Mitchell M, Cashman KS, Gardner DK, Thompson JG, Lane M (2009) Disruption of mitochondrial malate-aspartate shuttle activity in mouse blastocysts impairs viability and fetal growth. Biol Reprod 80: 295-301.
37. Liu B, Chen Y, St Clair DK (2008) ROS and p53: a versatile partnership. Free Radic Biol Med 44: 1529-1535.
38. Elorza A, Hyde B, Mikkola HK, Collins S, Shirihai OS (2008) UCP2 modulates cell proliferation through the MAPK/ERK pathway during erythropoiesis and has no effect on heme biosynthesis. J Biol Chem 283: 30461-30470.
39. Borard M., Humm S, Newsholme EA. (1990) Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells. Biochem J 265: 503-509.
40. Mares-Perlman JA, Shrago E (1988) Energy substrate utilization in freshly isolated Morris Hepatoma 7777 cells. Cancer Res 48: 602-608.
41. Reitzer LJ, Wice BM, Kennell D (1979) Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem 254: 2669-2676.
42. Linder-Horowitz M, Knox WE, Morris HP (1969) Glutaminase activities and growth rates of rat hepatomas. Cancer Res 29: 1195-1199.
43. Sabine JR (1976) Metabolic controls in precancerous liver-VII. Time course of loss of dietary feedback control of cholesterol synthesis during carcinogen treatment. Eur J Cancer 12: 299-303.
44. Coleman PS, Lavietes BB (1981) Membrane cholesterol, tumorigenesis, and the biochemical phenotype of neoplasia. CRC Crit Rev Biochem 11: 341-393.
45. Solomon KR, Pelton K, Boucher K, Joo J, Tully C, et al. (2009) Ezetimibe is an inhibitor of tumor angiogenesis. Am J Pathol 174: 1017-1026.
46. Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7: 763-777.
47. Griffin JL, Bonney SA, Mann C, Hebbachi AM, Gibbons GF, et al. (2004) An integrated reverse functional genomic and metabolic approach to understanding orotic acid-induced fatty liver. Physiol Genomics 17: 140-149.
48. Ahmed N, Weidemann MJ (1995) Biochemical effect of three different inhibitors of purine/pyrimidine metabolism on differentiation in HL60 cells. Leuk Res 19: 263-273.
49. Huang M, Wang Y, Collins M, Mitchell BS, Graves LM (2002) A77 1726 induces differentiation of human myeloid leukemia K562 cells by depletion of intracellular CTP pools. Mol Pharmacol 62: 463-472.
50. Racke FK, Wang D, Zaidi Z, Kelley J, Visvader J, et al. (2001) A potential role for protein kinase C-epsilon in regulating megakaryocytic lineage commitment. J Biol Chem 276: 522-528.
51. Matsumura I, Kawasaki A, Tanaka H, Sonoyama J, Ezoe S, et al. (2000) Biologic significance of GATA-1 activities in Ras-mediated megakaryocytic differentiation of hematopoietic cell lines. Blood 96: 2440-2450.
52. Kim KW, Kim SH, Lee EY, Kim ND, Kang HS, et al. (2001) Extracellular signal-regulated kinase/90-KDA ribosomal S6 kinase/nuclear factor-kappa B pathway mediates phorbol 12-myristate 13-acetate-induced megakaryocytic differentiation of K562 cells. J Biol Chem 276: 13186-13191.
53. Kawano T, Horiguchi-Yamada J, Saito S, Iwase S, Furukawa Y, et al. (2004) Ectopic cyclin D1 expression blocks STI571-induced erythroid differentiation of K562 cells. Leuk Res 28: 623-629.
54. Kawano T, Horiguchi-Yamada J, Iwase S, Furukawa Y, Kano Y, et al. (2004) Inactivation of ERK accelerates erythroid differentiation of K562 cells induced by herbimycin A and STI571 while activation of MEK1 interferes with it. Mol Cell Biochem 258: 25-33.
55. Jacquel A, Herrant M, Legros L, Belhacene N, Luciano F, et al. (2003) Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage. FASEB J 17: 2160-2162.
56. Witt O, Sand K, Pekrun A (2000) Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. Blood 95: 2391-2396.
57. Woessmann W, Zwanzger D, Borkhardt A (2004) ERK signaling pathway is differentially involved in erythroid differentiation of K562 cells depending on time and the inducing agent. Cell Biol Int 28: 403-410.
58. Jacquel A, Herrant M, Defamie V, Belhacene N, Colosetti P, et al. (2006) A survey of the signaling pathways involved in megakaryocytic differentiation of the human K562 leukemia cell line by molecular and c-DNA array analysis. Oncogene 25: 781-794.
59. Root DE, Hacohen N, Hahn WC, Lander ES, Sabatini DM (2006) Genomescale loss-of-function screening with a lentiviral RNAi library. Nat Methods 3: 715-719.
60. Ren JG, Li Z, Sacks DB (2007) IQGAP1 modulates activation of B-Raf. Proc Natl Acad Sci U S A 104: 10465-10469.
61. Benson JD, Chen YN, Cornell-Kennon SA, Dorsch M, Kim S, et al. (2006) Validating cancer drug targets. Nature 441: 451-456.
62. Park JI, Choi HS, Jeong JS, Han JY, Kim IH (2001) Involvement of p38 kinase in hydroxyurea-induced differentiation of K562 cells. Cell Growth Differ 12: 481-486.
63. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, et al. (2006) Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10: 241-252.
64. Verrax J, Stockis J, Tison A, Taper HS, Calderon PB (2006) Oxidative stress by ascorbate/menadione association kills K562 human chronic myelogenous leukaemia cells and inhibits its tumour growth in nude mice. Biochem Pharmacol 72: 671-680.
65. Luo B, Groenke K, Takors R, Wandrey C, Oldiges M (2007) Simultaneous determination of multiple intracellular metabolites in glycolysis, pentose phosphate pathway and tricarboxylic acid cycle by liquid chromatography-mass spectrometry. J Chromatogr A 1147: 153-164.